The abstract submission entitled, "Optimising phase 3 dose selection with ITCA 650: correlation between baseline HbA1c and reduction of HbA1c after 24 weeks of treatment," by R.R. Henry, J. Rosenstock, M. Baron, K. Luskey, and T. Alessi, was accepted for an oral presentation. The presenting author will be Robert R. Henry, MD, Chief of the Section of Diabetes, Endocrinology and Metabolism at the University of California, San Diego. The presentation (number 109) will take place in the Langerhans Hall, on Wednesday October 3, 2012, in Session OP 19 (Novel Therapies) from 2:30 PM - 4:00 PM Session.
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012. The analysis was performed to facilitate selection of a dosing regimen to be further examined the ITCA 650 global phase 3 clinical program.